Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay
First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients ANN ARBOR, MI / ACCESS Newswire...
Day: September 23, 2025
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic...
InnovAge Appoints Meredith Delk as Executive Vice President and Chief Administrative Officer
DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
ALPINE WHITE brings Brazil its first peroxide-free dental whitening strips
Swiss oral-care brand launches a clinically tested at-home whitening range, now available at leading pharmacy chains nationwideRIO DE JANEIRO, Sept....
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Vanderbilt Report: Full Alliance Group helps Power Hypochlorous Acid’s Breakout from Hospitals to the Global Consumer Market
BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Once relegated to the back rooms of hospitals, hypochlorous acid (HOCl) is...
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept....
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product...
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced...
PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE
COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:...
General Oncology Announces Formation of Scientific Advisory Board
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for...
High Stakes, High Impact: $20 million from the Weston Family Foundation awarded to cutting-edge health research projects at the forefront of innovation
McGill University and University of Alberta each awarded $10M to pursue bold research with transformational potential to redefine health outcomes...
Umoja Biopharma Named One of 2025’s Most Promising Biotech Companies by Endpoints News and Fierce Biotech
SEATTLE, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the...
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated...
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the...
Altimmune to Participate in Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based...
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients...
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation...